Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.

Conditions

Renal Cell Cancer
Melanoma
Non-Small-Cell Lung Cancer
Hepatocellular Cancer
Bladder Cancer
Sarcoma
Head and Neck Cancer
Colorectal Cancer
Ovarian Cancer
Squamous Cell Carcinoma

Interventions

BIOLOGICAL: PF-07263689
BIOLOGICAL: Sasanlimab

Sponsor

Pfizer